Literature DB >> 4804283

Technical aspects of the macrophage electrophoretic mobility (MEM) test for malignant disease.

J A Pritchard, J L Moore, W H Sutherland, C A Joslin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1973        PMID： 4804283      PMCID： PMC2149080     

Source DB:  PubMed          Journal:  Br J Cancer Suppl        ISSN： 0306-9443


× No keyword cloud information.
  5 in total

1.  Macrophage-electrophoretic-mobility (M.E.M.) test for malignant disease. An independent confirmation.

Authors:  J A Pritchard; J L Moore; W H Sutherland; C A Joslin
Journal:  Lancet       Date:  1972-09-23       Impact factor: 79.321

2.  The mechanism of antigen-induced electrophoretic mobility reduction of guinea-pig macrophages.

Authors:  E A Caspary
Journal:  Clin Exp Immunol       Date:  1972-06       Impact factor: 4.330

3.  Lymphocyte sensitisation: an in-vitro test for cancer?

Authors:  E J Field; E A Caspary
Journal:  Lancet       Date:  1970-12-26       Impact factor: 79.321

4.  Lymphocyte sensitization in advanced malignant disease: a study of serum lymphocyte depressive factor.

Authors:  E J Field; E A Caspary
Journal:  Br J Cancer       Date:  1972-06       Impact factor: 7.640

5.  Evaluation and development of the macrophage electrophoretic mobility (MEM) test for malignant disease.

Authors:  J A Pritchard; J L Moore; W H Sutherland; C A Joslin
Journal:  Br J Cancer       Date:  1973-01       Impact factor: 7.640
  5 in total
  13 in total

1.  Macrophage electrophoretic mobility (MEM) test in malignant gynaecological diseases.

Authors:  H L Jenssen; H Köhler; J Günther; B Klausch; W Straube; R Hofmann; H H Büttner
Journal:  Arch Gynakol       Date:  1976-03-05

2.  [The electrophoretic-mobility-(EM) test: a method for discrimination of malignant and non-malignant tumors (author's transl)].

Authors:  C Tautz; W Schneider; E Laier; G Brügmann
Journal:  Klin Wochenschr       Date:  1978-02-15

3.  The macrophage electrophoretic mobility (MEM) test for malignant disease. Further clinical investigations and studies on macrophage slowing factors.

Authors:  A W Preece; P A Light
Journal:  Clin Exp Immunol       Date:  1974-12       Impact factor: 4.330

4.  Studies with the macrophage migration inhibition (MMI) test in patients with malignant disease.

Authors:  P A Light; A W Preece; H A Waldron
Journal:  Clin Exp Immunol       Date:  1975-11       Impact factor: 4.330

Review 5.  Human tumour-associated and tumour-specific antigens: some concepts in relation to clinical oncology.

Authors:  A M Neville; A M Mackay; J Westwood; C Turberville; D J Laurence
Journal:  J Clin Pathol Suppl (Assoc Clin Pathol)       Date:  1975

6.  [Demonstration of a factor in cerebrospinal fluid with inhibitory activity for electrophoretic cell mobility in multiple sclerosis (author's transl)].

Authors:  H L Jenssen; H J Meyer-Rienecker; H Werner
Journal:  J Neurol       Date:  1976-11-26       Impact factor: 4.849

7.  Cellular immunity to myelin basic protein in man and in animal model systems as measured by the macrophage migration inhibition test.

Authors:  J B Shelton; C W Potter; I Carr
Journal:  Br J Cancer       Date:  1975-05       Impact factor: 7.640

8.  Failure to obtain positive MEM tests in either cell-mediated immune conditions in the guinea-pig or in human cancer.

Authors:  H Arvilommi; M M Dale; H N Desai; J L Mongar; M Richardson
Journal:  Br J Cancer       Date:  1977-11       Impact factor: 7.640

9.  Human peripheral lymphocytes and cancer. In vitro studies on the basic protein, histone F2A1 fraction.

Authors: 
Journal:  Br J Cancer       Date:  1974-09       Impact factor: 7.640

10.  Cellular immunity to encephalitogenic factor as measured by macrophage migration inhibition during tumour induction and growth.

Authors:  D J Flavell; J Goepel; C W Potter; I Carr
Journal:  Br J Cancer       Date:  1978-05       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.